Home
About
Overview
Sharing Data
ORCID
Help
History (28)
Protein Kinase Inhibitors
Hospital Costs
Clemastine
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
See All 28 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Adv Ther. 2021 07; 38(7):3724-3742.
View in:
PubMed
subject areas
Humans
Immunologic Factors
Magnetic Resonance Imaging
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Natalizumab
Treatment Outcome